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Optimum strategies to elicit and maintain antibodies at mucosal portals of virus entry are critical for the
development of vaccines against human immunodeﬁciency virus (HIV). Here we show in non-human
primates that a novel regimen of repeated intravaginal delivery of a non-adjuvanted, soluble recombi-
nant trimeric HIV-1 clade C envelope glycoprotein (gp140) administered in Carbopol gel can primeccepted 13 December 2010
vailable online 25 December 2010
eywords:
mmunisation
CN54
for B-cell responses even in the absence of seroconversion. Following 3 cycles of repeated intravaginal
administration, throughout each intermenses interval, 3 of 4 macaques produced or boosted systemic
and mucosally-detected antibodies upon intramuscular immunisation with gp140 formulated in AS01
adjuvant. Reciprocally, a single intramuscular immunisation primed 3 of 4 macaques for antibody boost-
ing after a single cycle of intravaginal immunisation. Virus neutralising activity was detected against
enve
agina
IV-gp140 clade C and clade B HIV-1
. Introduction
The induction of responses that protect at mucosal portals of
irus entry poses a particular problem for vaccine design anddevel-
pment. Nowhere is this more critically highlighted than in the
earch for an HIV vaccine where prevention of infection at, and/or
apid clearance from, the mucosal surface may be essential for
accine efﬁcacy. Ideally an effective vaccine would induce virus
eutralising activity in the ﬂuids present at susceptible mucosal
urfaces such as the lower female genital tract. Despite over 20
ears of intensive research, this is proving to be a complex prob-
em with many roadblocks to progress. In part this is due to the
articular biology of HIV including (1) the structure of the virus
lycoprotein spikes that are largely resistant to the induction and
ction of neutralising antibodies through conformational masking
1,2], glycan shielding [3,4] and sequence hypervariability [5]; (2)
he rapid dissemination of virus from mucosal sites of infection
6–8] and (3) the potential for HIV to evade antibody through inti-
ate cell-to-cell spread (reviewed in Martin and Sattentau [9]).
∗ Corresponding author. Tel.: +44 020 82666415; fax: +44 020 8266 6419.
E-mail address: mcranage@sgul.ac.uk (M.P. Cranage).
264-410X © 2010 Elsevier Ltd. 
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Open access under CC BY license.lopes but was restricted to highly neutralisation sensitive pseudoviruses.
© 2010 Elsevier Ltd. 
However, signiﬁcant progress is being made. Examples of broadly
reactive virus-neutralising antibodies and their cognate epitopes
are increasingly being described [10–12] and signiﬁcantly, pro-
tective efﬁcacy has been reported in macaques against vaginal,
oral and rectal challenge with HIV-simian immunodeﬁciency (SIV)
Env-chimeric viruses (SHIVs) following intravenous infusion of
neutralising monoclonal antibodies [13–17].
A further signiﬁcant roadblock to progress, addressed in the
study reported here, is how to induce and maintain anti-HIV anti-
body responses at mucosal surfaces. Not only is there a lack of
licensed mucosal adjuvants but there is also the danger of cre-
ating additional targets for HIV-infection through the activation
and/or recruitment of local T cells, a potential problem highlighted
in the STEP IIb clinical trial using recombinant adenovirus 5 (Ad5)
vectors [18]. Furthermore, mucosal effector B-cell responses are
relatively short-lived. Thus, for pathogens such as HIV, that gain
direct access to the immune system, it may be necessary to pro-
vide repeated or sustained stimulation of local speciﬁc immunity
Open access under CC BY license.in the absence of generalised inﬂammation tomaintain a protective
antibody response. We are addressing this issue in animal models
and in women using vaginal immunisation with stable recombi-
nant HIV-1CN54 clade C trimeric gp140 produced in CHO cells. A
clade C product was chosen based upon the high prevalence of this
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IV-1 subtype globally. To minimise the chance of causing local
nﬂammation, the antigen is formulated in a poly-acrylic acid (Car-
opol) gel, an excipient licensed for vaginal use inwomen. Because,
n women, the efﬁciency of vaginal immunisation is inﬂuenced by
he menstrual cycle [19,20], formulated antigen is administered
epeatedly throughout the intermenses interval to ensure exposure
t the optimal time. Thus, a single cycle of immunisation consists
f 9 exposures intravaginally. We have reported previously that a
ingle cycle of repeated intravaginal administration of this formu-
ation was sufﬁcient to reproducibly induce antibody responses in
abbits [21]. The data, from this pre-clinical vaginal irritancy study,
roved the concept that exposure of the female genital tract to
on-adjuvanted recombinant HIV gp140 can induce systemic and
ucosally-detectable antibodies and showed that the formulation
as well tolerated. However, ovulation is coitally-induced in rab-
its and the anatomy of the rabbit female genital tract may favour
ntigen uptake, being markedly different to that of women [22].
Here we have immunised cynomolgus macaques intravagi-
ally with trimeric HIV-1CN54 gp140 mixed with Carbopol gel
sing a protocol identical to that used in a clinical trial run in
arallel. Although the present study was not designed for virus
hallenge, it is important to compare immunogenicity in macaques
nd humans so that subsequent vaccine efﬁcacy studies with SIV
r SHIVs [23] can be fully interpreted. Moreover, this strategy
ffords the opportunity to iteratively evaluate variations of the
accine protocol before moving the most promising options to
uman phase 1 studies and to macaque virus challenge studies.
e have used the macaque model to determine the effects of
ultiple cycles of intravaginal immunisation and the effects of
ubsequent and prior intramuscular immunisation with trimeric
p140 formulated in the GSK Biologicals AS01 Adjuvant Sys-
em containing liposomes, monophosphoryl lipid A (MPL) and
uillaja saponaria fraction 21 (QS21) [24,25]. We show that sys-
emic and mucosally-detected IgG and IgA responses are induced
n a proportion of animals after repeated vaginal exposure to
IV-1 clade C envelope formulated in a Carbopol gel and were
fﬁciently boosted by subsequent intramuscular immunisation
ith adjuvanted gp140. Furthermore, intravaginal immunisation
ould prime, without prior seroconversion, for a memory response
evealed by intramuscular immunisation. Reciprocally, a single
ntramuscular immunisation primed for intravaginal boosting.
. Materials and methods.1. HIV gp140
A clade C envelope clone p97CN54 was obtained originally from
Chinese patient [26,27] and was made available by H. Wolf and
. Wagner, University of Regensburg, Germany. Trimeric gp140
able 1
ssignment of animals to experimental groups.
Group Macaque numbers Day of
A E53, E54, E55, E56 0–21
63–11
131–1
281
B E49, E50, E51, E52 0
70–10
C E57, E58, E59, E60 0
28
84
128–1
D E107, E108 0
a For any one animal intravaginal (ivag) immunisation was done 9 times over a 19-day
b Each ivag dose consisted of 100g gp140 formulated in Carbopol gel.
c Intramuscular immunisation consisted of 100g gp140 formulated in AS01 adjuvant29 (2011) 1421–1430
(gp120 plus ED of gp41), designated as CN54 gp140, was produced
in CHO cells as a recombinant product and manufactured to good
manufacturing practice speciﬁcation by Polymun Scientiﬁc, Vienna
Austria. The ﬁdelity of the product was conﬁrmed by mass spectro-
metric analysis of tryptic fragments, by the Medical Biomics Centre
at SGUL.
2.2. Animals
Fourteen UK captive-bred female cynomolgus macaques
(Macaca fascicularis), aged between 4 and 5 years at the beginning
of theexperiment,werehoused inaccordancewith theHomeOfﬁce
(UK) Code of Practice (1989). Animals were sedated with ketamine
hydrochloride prior to procedures. Menstrual cycles were deter-
mined by the onset of bleeding.
2.3. Immunisation
Animalswere assigned to experimental groups (Table 1). Immu-
nisation timings varied dependent upon individual menstrual
cycles. Gp140 was formulated at 100gml−1 in Carbopol gel as
described previously [21]. 1ml of the mixture was administered
via a syringe inserted approximately 2 cm into the vagina. For any
one cycle of intravaginal inoculation, animals received formulated
product on 9 occasions at 2–3 daily intervals during the inter-
menses phase of the menstrual cycle. For systemic immunisation,
100g gp140 was mixed with an equal volume of AS01 adjuvant
and 0.2ml injected into each deltoid muscle.
2.4. Genital tract secretions
Secretions were sampled using pre-weighed Weck-cel surgi-
cal spears (Medtronic Ophthalmics, Jacksonville, FL) placed either
on the cervical os or the vaginal wall for 1min. After reweighing,
secretions were eluted from the sponges as described previously
[21]. 8l of heat inactivated foetal calf serum was added to pooled
extracts before freezing aliquots at −80 ◦C.
2.5. Total immunoglobulin and anti-gp140 binding antibody
assays
Total immunoglobulin concentrations in mucosal eluates were
measured by sandwich ELISA. 96-well plates (medium binding,
Greiner Bio-One, Stonehouse, UK) were coated with either goat
anti-monkey IgG (-chain-speciﬁc) (KPL, Gaithersburg, USA) or
goat anti-monkey IgA (-chain-speciﬁc) (KPL) at 2gml−1. After
washing and blocking, as detailed below for antibody ELISA,
mucosal eluates were added at dilutions of 1/100 and 1/1000.
Bound immunoglobulin was detected by addition of goat anti-
immunisationa Route of immunisation
ivagb 9×
7 ivag 9×
70 ivag 9×
imc
im
1 ivag 9×
im
im
im
61 ivag 9×
im
interval; the exact start times varied depending upon the menstrual cycle.
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onkey IgG (Fc-speciﬁc) HRP conjugate (AbD Serotec, Kidlington,
K) or goat anti-monkey IgA (Fc-speciﬁc) HRP conjugate. Standard
urves were derived using puriﬁed rhesus monkey IgG (Southern-
iotech, Birmingham, USA) or puriﬁed human IgA (Sigma, UK) and
oncentrations inmucosal secretions calculated taking intoaccount
he dilution factor derived from the weight of sample. Due to the
navailability of puriﬁed monkey IgA, results for this isotype were
xpressed as units (U) ml−1.
Anti-gp140 binding antibodies were measured using a stan-
ardised ELISA. 96-well plates were coated with 50l per well
f recombinant CN54gp140 at 5gml−1 in PBS for 1h at 37 ◦C.
fter washing four times in PBS containing 0.05% Tween 20 (PBS-T)
eactive sites were blocked by incubation with PBS-T contain-
ng 10% foetal calf serum for 1h at 37 ◦C. After further washing,
erial dilutions of serum or mucosal eluates in PBS-T were added
nd incubated for 1h at 37 ◦C. Bound IgG was detected with goat
nti-monkey IgG (Fc-speciﬁc) HRP conjugate (Serotec) and bound
gA was detected with goat anti-monkey IgA (-chain-speciﬁc)
iotin conjugate (Acris, Herford, Germany) followed by avidin–HRP
onjugate (Sigma). Normal control monkey serum was used as a
egative control. Standard curves were derived using serum from
macaque immunised with HIV-1W61D gp120 [28]. Antibody titres
nd concentrations of immunoglobulin were corrected for dilu-
ion factor derived from weight of sample/weight of sample +600
ssuming a density of 1mgl−1 [19].
.6. Virus infectivity neutralisation assay
Neutralising antibody responses were measured against tier 1
nd tier 2 HIV-1 envelope-pseudotyped viruses, prepared by trans-
ectionof 293T/17 cells, using a standardised luciferase-basedassay
n TZM.bl cells [29,30]. The 50% inhibitory concentration (IC50) titre
as calculated as the dilution of serum that gave a 50% reduction
n relative luminescence units (RLU) compared to the virus control
ells after subtraction of cell control RLUs. Murine leukaemia virus
MuLV) negative controls were included in all assays.
.7. Extraction of tissue mononuclear cells and ELISpot assay
Dissected spleen tissue and lymph nodes or marrow washed
rom the bone were dissociated in RPMI by sieving through a
00m mesh and then centrifuged at 4 ◦C for 10min at 400× g.
upernatant was removed and the pellet resuspended in residual
edia and washed once more with 10ml RPMI. Cells were resus-
ended in25mlRPMIandwere thenﬁltered througha50mﬁlcon
BDBiosciences, Oxford,UK) before being layeredontoHistopaque-
077 (Sigma, UK) and centrifuged at room temperature for 30min
t 1500× g. Interface cells were collected and viable mononuclear
ells counted.
Ex vivo ampliﬁed ELISpot assays were based on the method
escribed by Bergmeier et al. [31]. PVDF membrane plates (Mulis-
reen HTSIP, Millipore) were treated with 35% ethanol for 1min,
ashed three times with sterile PBS and coated with either recom-
inant CN54 gp140 or KLH (Calbiochem) at 10gml−1 overnight
t 4 ◦C. Following a further 6 washes with PBS-T, reactive sites
ere blocked by incubation with RPMI 1640 medium containing
0% FCS and pen/strep for 1h at room temperature. Freshly recov-
red tissue MNCs were added to triplicate wells at 1×105 and
×105 cells/well and incubated for 24h at 37 ◦C in an atmosphere
f 5% CO2. After further washing in PBS-T, bound secreted anti-
odywas detectedwith either goat anti-monkey IgG-HRP (Serotec)
iluted 1/2000 or with goat anti-monkey IgA-biotin (Acris) at
/1000 followed by avidin–HRP (Sigma) diluted 1/2000. Spotswere
etectedby addition of TMB substrate (Sureblue TMB1-component
eroxidise substrate, KPL) and enumerated with a reader. Total
gG and IgA ASC were assayed by the same method using plates29 (2011) 1421–1430 1423
coated with goat anti-monkey IgG (-chain-speciﬁc) (KPL) or goat
anti-monkey IgA (-chain-speciﬁc) (KPL) as capture antibodies.
2.8. Statistical analysis
Speciﬁed analyses were performed using SigmaPlot version 11
software.
3. Results
3.1. Repeated cycles of intravaginal immunisation primed a
serum antibody response
Four cynomolgus macaques were inoculated intravaginally,
each with 1ml Carbopol gel containing 100g of CN54 gp140 on
each of 9 occasions every 2 or 3 days during the inter-menses inter-
val, followed by a further two cycles of intravaginal dosing and a
ﬁnal intramuscular immunisationwith100gofCN54gp140given
in AS01 adjuvant (Group A: Table 1).
All pre-treatment samples tested negative for gp140-speciﬁc
IgG and IgA antibodies. Two animals of Group A mounted serum
IgG and IgA anti-gp140 responses after multiple cycles of intrav-
aginal immunisation: E54 after two cycles and E55 after 3 cycles
(Fig. 1). IgG and IgA titres measured at the time of seroconversion
(2800, 1200; IgGand770, 320; IgA) fellwithin the range seen in sera
from animals of Groups B, C and D following a single adjuvanted
intramuscular immunisation (1110–5500; IgG and 75–6200; IgA)
(Figs. 2 and 3). Titres were boosted in E54 after the third cycle
of intravaginal immunisation and were similar to those measured
in Group C after two adjuvanted intramuscular immunisations. In
contrast, animals E53 and E56 did not seroconvert until given a
ﬁnal intramuscular immunisation. Of note however, peak titres of
IgG measured in sera from all the Group A animals 34 days after
intramuscular immunisation, regardless of prior seroconversion
status, were consistently higher than those measured in Groups
B, C and D after a single intramuscular immunisation [geometric
mean titre (gmt) 51,880 versus 2198, P<0.001; t-test]. Although
the gmt serum IgA response was also higher (1778 versus 245) this
difference did not reach statistical signiﬁcance (P=0.065; t-test).
Interestingly, animal E53, despite lack of seroconversion follow-
ing intravaginal immunisation, demonstrated anamnestic IgG and
IgA antibody responses after intramuscular immunisation, with
responses detected by 5 days.
Taken together these data indicate that non-adjuvanted, intrav-
aginal immunisation can result in seroconversion and, when this
does occur, IgG and IgA antibody titres are similar to those
measured after a single adjuvanted intramuscular immunisation.
Moreover, intravaginal immunisation in the absence of serocon-
version can prime for a systemic memory response.
3.2. Anti-gp140 antibody was detected in female genital
secretions following intravaginal vaccination only in animals that
seroconverted
IgG and IgA antibodies were detected in cervical and vagi-
nal samples intermittently from animals E54 and E55 following
intravaginal immunisation. In general, antibodies were detected
locally only upon seroconversion; however, in E54 IgG antibody
was detected at low titres (24–58) in cervical samples after a single
cycle of intravaginal immunisation and prior to seroconversion. In
E55, IgG antibody was detected in both cervical and vaginal sam-
ples immediately upon seroconversion but not on7other occasions
tested after seroconversion until intramuscular immunisation. IgA
antibody was detected in cervical samples with titres ranging from
103 to 242 on 3 of 8 occasions tested but only on one occasion
from vaginal samples. IgG and IgA antibodies were detected at a
1424 M.P. Cranage et al. / Vaccine 29 (2011) 1421–1430
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mmunisation cycles, each consisting of 9× 100g gp140, are shown as broad stip
nimal, E53, E54, E55 and E56 results are shown for serum and cervical and vaginal
etection for serum antibodies were titres of 100 and 10 for IgG and IgA respective
igher frequency in cervical and vaginal samples from E54 follow-
ng intravaginal immunisation; however, titres ﬂuctuated between
ositive peak values of IgG in the range 24–295 in cervical samples
nd59–563 in vaginal samples toundetectable and similarly for IgA
n the range 50–169 in cervical and 53–264 in vaginal samples to
ndetectable. There was no consistent pattern associating samples
n which antibody was below the limit of detection with either the
eight of the sample recovered or the total IgG or IgA content.
.3. Intramuscular immunisation augmented mucosally-detected
ntibody responses in macaques primed intravaginally
Intramuscular immunisation of animals in Group A resulted in
he appearance or the boosting of mucosally-detected antibod-
es in 3 of the 4 macaques. Furthermore, antibody titres were
ore stable than those seen after intravaginal immunisation alone
ver the study period (Fig. 1). Interestingly, in E53, where serum
ntibodies were undetectable before intramuscular boosting but
howed an anamnestic response upon boosting, only IgG anti-
ig. 2. Serum and mucosally-detected anti-gp140 antibody titres after a single intramu
ntramuscular immunisation alone (Group D). The intramuscular immunisation is indicat
00g gp140, is shown as a broad stippled area. For each animal, E49, E50, E51, E52 (Gr
aginal ﬂuids, with IgG indicated by ﬁlled symbols and IgA indicated by open symbols. L
espectively.unisation followed by intramuscular immunisation (Group A). The intravaginal
reas and intramuscular immunisation is indicated by a thin stippled line. For each
, with IgG indicated by ﬁlled symbols and IgA indicated by open symbols. Limits of
body was detectable locally despite total IgA concentrations of
2118–70,528Uml−1 and 1338–28,838Uml−1 in cervical and vagi-
nal samples respectively (Table 2). The IgG antibody was unlikely
due to blood contamination as in only one cervical sample was
haemoglobin detected. In the two animals in which antibody had
previously been detected mucosally both IgG and IgA antibody
titres were boosted. In E54, peak titres for IgG antibody of 2500
and 5582 were detected in cervical and vaginal samples respec-
tively compared to peak titres of 295 and 563 respectively prior to
intramuscular boosting. Likewise IgA antibody peak titres of 1086
and 1522 were detected in cervical and vaginal samples respec-
tively compared to peak titres of 169 and 264 respectively prior
to intramuscular immunisation. Similarly in E55 peak titres for IgG
antibody increased from186 to 3360 and from528 to 1719 in cervi-
cal and vaginal samples respectively and for peak titres of IgA from
242 to 1243 and from 355 to 515 respectively. Despite accelerated
(anamnestic) serum responses following intramuscular boosting,
in no case was a local anamnestic response detected. Animal E56
had nomucosally-detected antibody despite seroconversion; how-
scular immunisation followed by intravaginal immunisation (Group B) or a single
ed by a thin stippled line and the intravaginal immunisation cycle, consisting of 9×
oup B) and E107 and E108 (Group D) results are shown for serum and cervical and
imits of detection for serum antibodies were titres of 100 and 10 for IgG and IgA
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nimal, E57, E58, E59 and E60 results are shown for serum and cervical and vaginal
etection for serum antibodies were titres of 100 and 10 for IgG and IgA respective
ver, total IgG and IgA concentrations were consistently low in
ucosal samples from this animal (Table 2). In contrast, IgG was
sually detected in both cervical and vaginal samples from Group
animals following a single intramuscular immunisation when
bserved over a similar period of time (Fig. 2), but in any one
nimal this was irregular and overall at much lower titres than
etected in animals E53, E54 and E55 that had received intrav-
ginal priming (cervical gmt 63 versus 1298, and vaginal gmt 65
ersus 1511; P<0.001; Mann–Whitney rank sum test). Similarly,
here detected, cervical and vaginal IgA titres were higher when
ntramuscular immunisation was preceded by intravaginal prim-
ng; however the small sample size precluded statistical analysis.
.4. Serum and mucosally-detected anti-gp140 antibody
esponses were augmented by intravaginal immunisation of
acaques primed with a single intramuscular immunisation
To determine the effect of priming/pre-existing antibody on
ntravaginal immunisation, 4macaques received a single intramus-
ular immunisation 70–82 days prior to one cycle of intravaginal
mmunisation (Group B: Table 1) and a further 4 animals received 3
ntramuscular immunisations followed by a single cycle of intrav-
ginal immunisation 128–143 days after the last intramuscular
mmunisation (Group C: Table 1). Three of four animals of Group B
able 2
otal IgG and IgA concentrations in cervical and vaginal samples of each macaque.
Group Animal no. Total immunoglobulin concentration, m
IgG (g/ml)
Cervical Vaginal
A E53 683 (152–6156) 474 (99
E54 909 (218–2184) 493 (90
E55 653 (223–3650) 315 (37
E56 28 (9–112) 9 (5–
B E49 100 (15–309) 51 (4–
E50 2754 (1140–5429) 1785 (43
E51 191 (42–4949) 634 (39
E52 216 (66–1638) 272 (72
C E57 148 (10–710) 69 (13
E58 392 (22–1750) 82.6 (
E59 140 (38–529) 174 (26
E60 262 (90–1708) 92 (47
D E107 2295 (234–4592) 1167 (29
E108 1378 (314–2478) 924 (34ar immunisations followed by intravaginal immunisation (Group C). The intramus-
n cycle, consisting of 9× 100g gp140, is shown as a broad stippled area. For each
, with IgG indicated by ﬁlled symbols and IgA indicated by open symbols. Limits of
had signiﬁcantly higher serum IgG and IgA titres following intrav-
aginal administration of gp140 (IgG P=0.05, IgA P=0.039; paired
t test) (Fig. 2). In contrast, none of the animals of Group C had
increased serum antibody following intravaginal administration
(Fig. 3). As would be expected, titres of serum IgG and IgA were
signiﬁcantly higher at the time of intravaginal immunisation in
animals of Group C that had received 3 intramuscular immunisa-
tions compared to those of Group B (IgG gmt: 18,197 versus 649,
P<0.001; IgA gmt: 1972 versus 173, P=0.027; t-test).
Results formucosally detectable antibodyweremore difﬁcult to
interpret given the variability seen at different sampling times and
on some occasions between cervical and vaginal samples taken at
the same time. All animals of Group B appeared to respond follow-
ing intravaginal immunisation, including E49 that did not show a
boost in serum antibody. This animal was unusual in that serum
IgA titres were similar to IgG titres and IgA titres were higher than
IgG titres in cervical and vaginal samples. Interestingly, total IgA
concentrations were not elevated in cervical or vaginal secretions
from this animal (Table 2) and signiﬁcant haemoglobin contamina-
tion was only seen at Day 126, when titres of anti-gp140 IgA in the
cervical sample had declined and were below the limit of detection
in the vaginal sample.
Mucosally-detected antibody responses were seen in all ani-
mals of Group C following intramuscular immunisation. In most
edian (range)
IgA (U/ml)
Cervical Vaginal
–2435) 11,654 (2118–70,528) 9152 (1338–28,838)
–1788) 28,490 (6186–64,736) 19,920 (8525–116,965)
–1925) 27,790 (8752–81,942) 28,143 (4211–141,878)
114) 933 (400–3770) 619 (265–4018)
201) 938 (300–15,939) 1512 (148–13,300)
2–4579) 4832 (1935–6704) 4587 (763–13,552)
–2486) 4366 (799–49,625) 5328 (1607–44,455)
–966) 3345 (724–17,451) 2821 (1584–14,805)
–147) 1594 (225–7341) 1214 (286–1525)
6–434) 10,245 (1562–44,098) 4134 (487–22,940)
–1853) 6711 (52–16,459) 5459 (630–18,113)
–444) 5597 (1265–33,572) 4388 (408–18,585)
4–1991) 15,340 (8059–29,253) 17,225 (3919–26,241)
1–2261) 7269 (4703–27,368) 9740 (4702–85,936)
1426 M.P. Cranage et al. / Vaccine 29 (2011) 1421–1430
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Fig. 4. Comparison of anti-gp140 speciﬁc antibodies and total immunoglobulins in vaginal and cervical secretions. Animals were immunised either once or three times by
intramuscular immunisation with gp-140 in AS01 adjuvant followed by a cycle of 9 intravaginal immunisations with gp140 in Carbopol gel (Groups B and C) (a) The median
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s ns, P=
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bitres of IgG and IgA antibodies were signiﬁcantly different at the P=0.006 (**) level
um test). (b) Total IgG concentrations were signiﬁcantly higher in cervical secretio
rom the two sites were not signiﬁcantly different, P=0.22. Group mean (- - -) and m
nstances antibodies appeared following the second immunisation,
ubsequently waned and recovered following a further intramus-
ular exposure. For logistical reasons it was not possible to obtain
ucosal samples immediately before intravaginal immunisation;
owever, antibodies were detected locally in all animals after
he cycle of intravaginal immunisation but peak titres were not
levated. Overall, 3 intramuscular immunisations before intravagi-
al boosting conferred no advantage over a single intramuscular
mmunisation in terms of either the frequency or titre of antibody
esponse detected in cervical and vaginal samples.
Overall in Groups C and D both IgG and IgA anti-gp140 anti-
ody titres were higher in cervical ﬂuids than vaginal ﬂuids, withG but were not signiﬁcantly different (ns) for IgA P=0.097 (Mann–Whitney ranked
0.001 (**) (Mann–Whitney ranked sum test). (c) Total IgA concentrations in ﬂuids
(—) titres are shown with box plots.
median titres of IgG of 80 and 24 and of IgA of 103 and 54 in
vaginal and cervical samples respectively (Fig. 4). This difference
however only reached statistical signiﬁcance for IgG. Comparison
for individual animals showed cervical samples to contain higher
titre antibody than vaginal samples on 76% and 85% of occasions
tested for IgG and IgA respectively. Likewise, total immunoglob-
ulin concentrations were higher in cervical compared to vaginal
samples (median IgG 392gml−1 and 239gml−1; median IgA
8752Uml−1 and 6657Uml−1 for cervix and vagina respectively)
but only reached statistical signiﬁcance for IgG (Fig. 4). Direct com-
parison of IgG titres with IgA titres in either site was not possible,
as the IgA antibody assay used an additional ampliﬁcation step that
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that mucosally-primed B cells may cross-over between compart-clade C HIV-1 MW963.26 pseudovirus and compared to serum IgG and IgA gp140
inding antibody titres from macaques immunised with gp140 by intravaginal-
ystemic (Group A) and systemic-intravaginal (Groups B and C) protocols.
ad previously been shown to give better discrimination between
ow positive results and background, non-speciﬁc binding. Com-
arison of total IgG and IgA concentrations was also precluded as a
uriﬁed cynomolgus macaque IgA was unavailable for calibration
f the IgA assay and therefore puriﬁed human IgA was used.
.5. Serum neutralising activity against tier 1 envelope
seudotype correlated with binding antibody titre in animals
rimed intramuscularly and demonstrated restricted speciﬁcity
Serum virus neutralising activity against clade C tier 1
W965.26 pseudovirus was induced in 2 of 4 animals of Group
, albeit only at very low titre in one animal, following adjuvanted
ntramuscular immunisation; in 3 of 4 animals of Group B at low
itre following intravaginal immunisation and in 4 of 4 animals
f Group C following 3 intramuscular immunisations – this activ-
ty was not boosted by subsequent intravaginal immunisation. No
ctivity was seen in animals of Group D 34 days after intramus-
ular immunisation (Table 3). In sera where neutralising activity
as detected above the cut-off titre of 60, strong correlations were
ound between this activity and both IgG (r=0.87, P<0.001) and
gA (r=0.82, P<0.001; Pearson product moment correlation) anti-
p140 binding titres (Fig. 5). In sera from animals of Groups B and
, anti-gp140 IgG titres greater than 3000 were invariably pre-
ictive of neutralising activity. Notably, this was not the case for
roup A, where despite the induction of high titres of anti-gp140
gG (16,000–134,000) following intravaginal immunisation, appre-
iable neutralising activity was detected only in animal E54 which
ad the highest binding antibody titre.
To determine the breadth of neutralising activity, sera were
ested against a range of pseudotypes including 4 other tier 1
nvelopes. Although no activity was seen against TV1.21, another
lade C envelope, some activity was detected against the clade
SF162.LS (Table 3), but not against clade B, BaL.26 or clade
, DJ263.8. Neither was any neutralising activity seen against
ny of 13 tier 2, clade C envelopes (96ZM651.02, Du156.12,
u172.17, Du422.1, CAP45.2.00.G3, CAP210.2.00.E8, ZM197M.PB7,
M214M.PL15, ZM233M.PB6, ZM249M.PL1, ZM53M.PB12,
M109F.PB4, ZM135M.PL10a). Cross-reactivity between clade
and clade B was restricted to sera with high-titre neutralisation
gainst MW965.26 (titres of 594–2846); however sera from animal
58, with titres within this range failed to cross-react.29 (2011) 1421–1430 1427
3.6. High frequencies of ex vivo IgG antibody secreting cells were
detected in iliac lymph nodes of intravaginally-primed macaques
that seroconverted only after intramuscular immunisation
To determine the distribution of ex vivo anti-gp140 speciﬁc anti-
body secreting cells (ASC),mononuclear cells (MNC)were obtained
from tissues of Groups A and D animals at necropsy. Insufﬁ-
cient cells were recovered from vagina and cervix; but MNC were
recovered from spleen, bone marrow, interior iliac lymph nodes,
mesenteric lymph nodes and axillary lymph nodes. Frequencies of
ASC ranged from52 to 1065 sfu/106 MNC for total IgG and from115
to 906 sfu/106 MNC for total IgA in all tissues other than bone mar-
row, where frequencies for both isotypes exceeded 2500/106 MNC
(Table 4). Inmost instances, only low frequencies of anti-gp140ASC
were detected; notably however, IgG anti-gp140-speciﬁc ASC rep-
resented 6% and 16% of total IgG secreting cells recovered from the
interior iliac lymph nodes of animals E53 and E56 respectively; the
animals that failed to seroconvert after intravaginal immunisation
but responded following intramuscular immunisation (Table 4).
4. Discussion
This is the ﬁrst demonstration that intravaginally delivered sol-
uble recombinant HIV-1 gp140 is immunogenic in primates in the
absence of a conventional mucosal adjuvant. Although intravagi-
nal immunisation alone was less efﬁcient in macaques compared
to in rabbits at inducing serum and mucosally-detected antibod-
ies, where a single cycle of immunisation was sufﬁcient to induce
responsiveness [21], women in a parallel clinical trial, were also
essentially unresponsive following a single cycle of immunisation
(Lewiset al., personal communication). Thismayreﬂect inefﬁciency
in accessing sites of inductive immunity, despite the strategy of
repeated inoculation designed to increase the likelihood of expo-
sure to immunogen during the menstrual cycle. However, there
may only be a narrow window for induction of immune func-
tion during any one cycle as shown by studies in women [19].
It was therefore encouraging that two macaques responded with
serum and mucosally-detected responses after multiple cycles of
intravaginal administration and that a third macaque was primed
for a response as revealed by subsequent intramuscular immu-
nisation. This “silent priming” of a memory B-cell response may
be similar to that observed in macaques following mucosal expo-
sure to “subinfectious” doses of SIV where antigen-primed B cells
were detected in vitro by ampliﬁed ELISpot in the absence of
seroconversion [32]. In the present study, for logistical reasons it
was not possible to sample lymphoid tissues over time; intrigu-
ingly however, high frequencies of gp140-speciﬁc IgG ASC were
detected postmortem in the interior iliac lymphnodes from the two
intravaginally immunised macaques that seroconverted only after
intramuscular immunisation. These lymphnodes,whichdrain both
the female genital and the rectal tracts, have been associated with
protective immunity in SIV challenge studies [33]. In the present
study we were unable to recover sufﬁcient cells directly from
cervico-vaginal tissues for ELISpot analysis and therefore assess-
ment of the frequency of mucosal ASC was not possible. However,
the appearance and apparent sustainability of mucosally-detected
antibodies after intramuscular boosting was encouraging and sug-
gested that immune cells may be homing to local tissue. Further
in vivo experiments are needed to establish the longevity and func-
tional activity of the mucosally-detected antibody. How mucosal
immunisationprimes for a systemic boost is unknownand suggestsments and/or that vaginally-administered antigen reaches both
systemic and mucosal sites of inductive immunity.
Conversely, the mechanism by which intramuscular immunisa-
tion primes antigen recognition following intravaginal exposure
1428
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Table 3
Serum virus neutralising activity.
Animal No. Day 0 (pre-imm.) Day 196 (26–47 days post 3× ivag) Day 281 (111–132 days post 3× ivag) Day 315 (34 days post 1× i.m.)
VNA Binding Ab VNA Binding Ab VNA Binding Ab VNA Binding Ab
Clade C
(MW965)
Clade B
(SF162)
IgG IgA Clade C
(MW965)
Clade B
(SF162)
IgG IgA Clade C
(MW965)
Clade B
(SF162)
IgG IgA Clade C
(MW965)
Clade B
(SF162)
IgG IgA
(a) Group A
E53 <60 <60 <100 <10 NT NT <100 <10 <60 <60 <100 <10 <60 <60 40,800 1370
E54 <60 <60 <100 <10 <60 <60 7600 940 <60 <60 3100 710 1980 151 134,000 16,000
E55 <60 <60 <100 <10 <60 <60 1200 120 288a 74a <100 70 72 <60 82,900 6300
E56 <60 <60 <100 <10 NT NT <100 <10 <60 <60 <100 <10 <60 <60 16,000 800
Animal No. Day 0 (pre-imm.) Day 64 (64 days post 1× i.m.) Day 99–115 (9–14 days post 1× ivag) Day 199 (98–110 days post 1× ivag)
VNA Binding Ab VNA Binding Ab VNA Binding Ab VNA Binding Ab
Clade C
(MW965)
Clade B
(SF162)
IgG IgA Clade C
(MW965)
Clade B
(SF162)
IgG IgA Clade C
(MW965)
Clade B
(SF162)
IgG IgA Clade C
(MW965)
Clade B
(SF162)
IgG IgA
(b) Group B
E49 <60 <60 <100 <10 <60 <60 1470 1810 65 <60 1200 720 <60 <60 450 190
E50 <60 <60 <100 <10 <60 <60 690 91 74 <60 2260 635 <60 <60 700 140
E51 <60 <60 <100 <10 <60 <60 420 45 115 <60 2130 980 <60 <60 400 200
E52 <60 <60 <100 <10 <60 <60 1330 156 <60 <60 2840 900 <60 <60 540 190
Animal No.Day 0 (pre-imm.) Day 98 (14 days post 3× i.m.) Day 134–148 (36–50 days post
3× i.m.)
Day 160–179 (13–22 days post
1× ivag)
Day 270–272 (111–127 days
post 1× ivag)
VNA BindingAbVNA Binding Ab VNA Binding Ab VNA Binding Ab VNA Binding Ab
Clade C
(MW965)
Clade B
(SF162)
IgG IgA Clade C
(MW965)
Clade B
(SF162)
IgG IgA Clade C
(MW965)
Clade B
(SF162)
IgG IgA Clade C
(MW965)
Clade B
(Sf162)
IgG IgA Clade C
(MW965)
Clade B
(SF162)
IgG IgA
(c) Group C
E57 <60 <60 <100 <10 1814 453 12,4400 8700 594 121 22,700 2900 159 <60 NT NT 196 <60 7600 590
E58 <60 <60 <100 <10 2128 <60 112,400 6400 761 <60 21,500 2560 517 <60 15,200 1950 192 <60 4300 400
E59 <60 <60 <100 <10 860 73 71,200 6400 216 <60 9360 1100 105 <60 4300 510 <60 <60 2000 140
E60 <60 <60 <100 <10 2846 96 127,600 11,200 1012 69 23,800 1880 651 <60 13,000 1550 125 <60 2100 190
Animal No. Day 0 (pre imm.) Day 34 (34 days post i.m.)
VNA Binding Ab VNA Binding Ab
Clade C
(MW965)
Clade B
(SF162)
IgG IgA Clade C
(MW965)
Clade B
(SF162)
IgG IgA
(d) Group D
E107 <60 <60 <100 <10 <60 <60 2000 120
E108 <60 <60 <100 <10 <60 <60 1600 190
Bold values indicate speciﬁc neutralisation with no background activity on MuLV pseudotype virus.
a Non-speciﬁc activity – VNA titre of 640 against MuLV pseudotype virus.
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Table 4
Distribution of gp140-speciﬁc antibody secreting cells after intramuscular alone and intramuscular (1×) and intravaginal immunisation.
Frequency of antibody secreting cells: gp140-speciﬁc (total): sfu/106
E53 E54 E55 E56 E107 E108
IgG IgA IgG IgA IgG IgA IgG IgA IgG IgA IgG IgA
Spleen 0 (995) 0 (101) 4 (120) 1 (496) 0 (1229) 0 (130) 12 (99) 0 (637) 4 (52) 0 (553) 0 (0) 0 (643)
Bone M 0() 2.5 () 42 () 22 () 0 () 12 () 2 () 1 () 5 () 12 () 0 () 1 ()
Iliac LN 41 (672) 0 (397) 7 (665) 5 (415) 0 (343) 0 (332) 75 (470) 0 (197) 0 (731) 0 (906) 2 (971) 0 (528)
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Ax LN 0(706) 0 (357) 0 (0) 1 (307) 0 (306)
s not established; however, the dose and secondary signalling
equirements for memory B-cell activation are less stringent than
or B cell priming. Presumably, despite the systemic route of prim-
ng, at least some memory cells migrate to the female genital
ract. It is also conceivable that antibody induced by intramuscu-
ar priming complexes to vaginally applied antigen and facilitates
ptake and presentation by Fc receptor-bearing APC. The enhanced
mmunogenicity of immune complexes in general when admin-
stered systemically is well documented and has recently been
eported for HIV-1 gp120 [34]; however, there is a paucity of data
egardingmucosal routes [35]. The lackofvaginalboostingof serum
esponses in macaques that had received 3 intramuscular immu-
isations may simply be a saturation effect; however, the lack of
ocal antibody boosting was disappointing and suggests that there
ay be downmodulation of local memory in the presence of high
evels of systemic immunity.
Taken together, the results suggest that the concentration of
p140 used for intravaginal immunisation may have been below
he threshold required for efﬁcient stimulation of an antibody
esponse de novo from the precursor B-cell pool and at the thresh-
ld for boosting a memory response. It would now be interesting
o determine if higher doses of non-adjuvanted gp140 would be
ore effective. Furthermore, although formulating gp140 in rheo-
ogically structured vehicles designed to enhance antigen retention
n the vaginal vault appeared to offer little advantage over Carbopol
ormulation in rabbits [36] such vehicles may be more beneﬁcial in
on-human primates and humans, where access to the immune
ystem via this route may be more restricted.
The mechanisms responsible for antibody appearance in cervi-
al and vaginal ﬂuids are yet to be fully deﬁned. Some antibody
s derived from plasma by transudation and some may be pro-
uced locally. Indeed, testing of secretions from6macaques,where
olume allowed, revealed IgA anti-gp140 containing secretory
omponent (datanot shown). For technical reasons itwasnotpossi-
le todirectly compare total and speciﬁc IgGand IgA levelshowever
thers have reported that, as in women [37], IgG is the predomi-
ant immunoglobulin in the lower female genital tract ofmacaques
38] and IgG as well as IgA ASC are present in macaque vaginal tis-
ues [39]. Also, as in women [40], both total and speciﬁc IgG and
gAwere found to be higher in cervical samples than in vaginal. The
ide variation in local immunoglobulin and antibody levels for any
ndividual animalmayhavebeendue to the effects of themenstrual
ycle as reported inmacaques andwomen [41,42,38]; however, the
resent study was not powered to analyse this variable.
An effective vaccine will require not only sustained antibody
roduction into mucosal ﬂuids but the antibodies will need to
ave potent and broad virus neutralising activity. It is known that
onomeric gp120 generally fails to elicit such activity [43–46]nd for this reason we used a trimeric envelope immunogen,
p140, that has demonstrated remarkable stability in vitro (D.
atinger, personal communication) and is therefore more likely
o mimic the native virion envelope spike [2]. Although cross-
lade neutralising activity was restricted to MW965.26 and clade98) 0 (1065) 0 (563) 0 (795) 2 (821) 0 (875) 0 (835)
15) 0 (356) 0 (141) 0 (325) 0 (275) 0 (523) 0 (409)
B SF162.LS envelope-bearing pseudoviruses and disappointingly
no activity was seen against any of a broad range of clade C
envelopes, this study has shown that this narrow speciﬁcity is
not exclusively due to formulation of the immunogen in Car-
bopol and/or the vaginal route of administration, as similar
results were obtained after intramuscular immunisation in the
presence of AS01 adjuvant. Moreover, as in rabbits [21], serum
antibodies did not recognise the highly immunogenic gp41-ED
residues 598–597 [47] (data not shown), suggesting that the
gp41 region of the molecule may be occluded possibly because
of the lack of membrane anchoring. Interestingly macaques have
been protected against vaginal challenge with SHIVSF162 follow-
ing systemic or nasal/systemic immunisation with HIV-1SF162 V2
gp140 and protection was associated with serum neutralising
antibody [48].
Although the restricted serum neutralising activity obtained
is of questionable relevance for a protective HIV-1 vaccine it is
interesting that the correlation between anti-gp140 IgG bind-
ing antibody titre and neutralising activity seen in animals that
were primed intramuscularly did not hold true for animals primed
intravaginally. This observation suggests factors other than anti-
body titre alone may be important, including antibody subclass,
avidity and ﬁne speciﬁcity. Furthermore, we were unable to mea-
sure neutralising activity in mucosal ﬂuids and there is a clear need
for thedevelopmentofmicro-neutralisationassays that canbeused
with small volumes of biological ﬂuid.
The results obtained here inform the design of our next clinical
trial that will run in parallel with a “paraclinical” macaque study
that will include envelope-SHIV challenge. Through this iterative
process it will be possible to cross-validate the macaque model –
essential for the identiﬁcation of correlates of protective immu-
nity. Moreover, although we cannot discount the possibility that
repeated sedation of the macaques may have inﬂuenced immune
responsiveness, our results support the idea thatmucosal exposure
to HIV, either at a subinfectious dose or in a “protected” form, for
example in the presence of a microbicide, may modulate speciﬁc
immunity and may augment vaccination.
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